Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

December 5, 2019

Study Completion Date

August 29, 2020

Conditions
PneumoniaAging
Interventions
BIOLOGICAL

Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein

One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23

BIOLOGICAL

Pneumococcal Vaccine Polyvalent

One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13

Trial Locations (1)

06030

UConn Center On Aging, Farmington

All Listed Sponsors
collaborator

UConn Health

OTHER

collaborator

University of Alabama at Birmingham

OTHER

lead

The Jackson Laboratory

OTHER

NCT03104075 - Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines | Biotech Hunter | Biotech Hunter